niacinamide has been researched along with 2019 Novel Coronavirus Disease in 17 studies
nicotinamide : A pyridinecarboxamide that is pyridine in which the hydrogen at position 3 is replaced by a carboxamide group.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, no new evidence has been found regarding the effect of niacinamide on lymphopenia in COVID-19 patients." | 5.51 | Efficiency of nicotinamide-based supportive therapy in lymphopenia for patients with ordinary or severe COVID-19: A randomized controlled trial. ( Han, YL; Hu, Q; Ma, Z; Peng, CF; Zhang, QY, 2022) |
| "Cutaneous lupus erythematosus is an umbrella term for a group of autoimmune connective tissue disorders affecting the skin." | 3.30 | Topical niacinamide (Nicotinamide) treatment for discoid lupus erythematosus (DLE): A prospective pilot study. ( Elshahid, AR; Kadah, AS; Nouh, AH; Zeyada, YA, 2023) |
| " During the observation period, no patient had any serious adverse events or side effects associated with taking the drug." | 3.01 | [The result of prospective randomized study CITADEL - the efficacy and safety of drug cytoflavin in postcovid rehabilitation]. ( Bairova, KI; Petrikeeva, AE; Putilina, MV; Shabalina, NI; Teplova, NV, 2021) |
| " This crucial role can be attributed to the gut microflora and its ability to shape human behavior and development by mediating the bioavailability of metabolites." | 2.66 | Minireview Exploring the Biological Cycle of Vitamin B3 and Its Influence on Oxidative Stress: Further Molecular and Clinical Aspects. ( Anton, E; Ciobica, A; Cojocariu, RO; Dhunna, N; Doroftei, B; Grab, D; Ilie, OD; Maftei, R; McKenna, J; Simionescu, G, 2020) |
| "Cytoflavin therapy at a dosage of 2 tablets 2 times a day for 25 days can be recommended as part of complex therapy for patients with DE and a COVID-19." | 1.91 | [Evaluation of the effectiveness of the drug Cytoflavin in patients with dyscirculatory encephalopathy who have undergone a new coronavirus infection]. ( Belova, LA; Dolgova, DR; Kruglova, LR; Kuvayskaya, AA; Mashin, VV; Plaksina, TD; Sukhikh, SS, 2023) |
| " This antiviral activity of LL37 is enhanced by the hydrotropic action of niacinamide, which may increase the bioavailability of the AMP." | 1.91 | Niacinamide enhances cathelicidin mediated SARS-CoV-2 membrane disruption. ( Ajnabi, J; Bhatt, T; Dam, B; Dias, PM; Ghatlia, N; Gulzar, SE; Jamora, C; Kataria, S; Khedkar, SU; Lall, S; Majumdar, A; Pandey, S; Raut, J; Sundaramurthy, V; Vemula, PK; Waskar, M, 2023) |
| "Niacin has a variety of uses, particularly in treating various skin conditions, including topically as an anti-acne treatment, promoting epidermal sphingolipid synthesis, moderating photoimmunosuppression, and reducing hyperpigmentation." | 1.91 | A Second Look at Niacin. ( Epstein, H, 2023) |
| "A 70-year-old man with newly diagnosed prostate cancer underwent 18F-PSMA-1007 PET/CT for staging." | 1.62 | COVID-19-Related Lung Parenchymal Uptake on 18F-PSMA-1007 PET/CT. ( Green, JS; Lyburn, ID; Nawwar, AA; Searle, J, 2021) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 17 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Putilina, MV | 1 |
| Teplova, NV | 1 |
| Bairova, KI | 1 |
| Petrikeeva, AE | 1 |
| Shabalina, NI | 1 |
| Ekusheva, EV | 1 |
| Voitenkov, VB | 1 |
| Rizakhanova, OA | 1 |
| Novak Kujundžić, R | 1 |
| Hu, Q | 1 |
| Zhang, QY | 1 |
| Peng, CF | 1 |
| Ma, Z | 1 |
| Han, YL | 1 |
| Nouh, AH | 1 |
| Elshahid, AR | 1 |
| Kadah, AS | 1 |
| Zeyada, YA | 1 |
| Belova, LA | 1 |
| Mashin, VV | 1 |
| Dolgova, DR | 1 |
| Kuvayskaya, AA | 1 |
| Kruglova, LR | 1 |
| Sukhikh, SS | 1 |
| Plaksina, TD | 1 |
| Boeri, M | 1 |
| Skelsey, MK | 1 |
| Schiro, JA | 1 |
| Dozier, SE | 1 |
| Glinert, R | 1 |
| Okun, MM | 1 |
| Bhatt, T | 1 |
| Dam, B | 1 |
| Khedkar, SU | 1 |
| Lall, S | 1 |
| Pandey, S | 1 |
| Kataria, S | 1 |
| Ajnabi, J | 1 |
| Gulzar, SE | 1 |
| Dias, PM | 1 |
| Waskar, M | 1 |
| Raut, J | 1 |
| Sundaramurthy, V | 1 |
| Vemula, PK | 1 |
| Ghatlia, N | 1 |
| Majumdar, A | 1 |
| Jamora, C | 1 |
| Epstein, H | 1 |
| Mehmel, M | 1 |
| Jovanović, N | 1 |
| Spitz, U | 1 |
| Doroftei, B | 1 |
| Ilie, OD | 1 |
| Cojocariu, RO | 1 |
| Ciobica, A | 1 |
| Maftei, R | 1 |
| Grab, D | 1 |
| Anton, E | 1 |
| McKenna, J | 1 |
| Dhunna, N | 1 |
| Simionescu, G | 1 |
| Zhao, H | 1 |
| Mendenhall, M | 1 |
| Deininger, MW | 1 |
| Blasco, H | 1 |
| Bessy, C | 1 |
| Plantier, L | 1 |
| Lefevre, A | 1 |
| Piver, E | 1 |
| Bernard, L | 1 |
| Marlet, J | 1 |
| Stefic, K | 1 |
| Benz-de Bretagne, I | 1 |
| Cannet, P | 1 |
| Lumbu, H | 1 |
| Morel, T | 1 |
| Boulard, P | 1 |
| Andres, CR | 1 |
| Vourc'h, P | 1 |
| Hérault, O | 1 |
| Guillon, A | 1 |
| Emond, P | 1 |
| Heer, CD | 1 |
| Sanderson, DJ | 1 |
| Voth, LS | 1 |
| Alhammad, YMO | 1 |
| Schmidt, MS | 1 |
| Trammell, SAJ | 1 |
| Perlman, S | 1 |
| Cohen, MS | 1 |
| Fehr, AR | 1 |
| Brenner, C | 1 |
| Badawy, AA | 1 |
| Suchard, MS | 1 |
| Savulescu, DM | 1 |
| Nawwar, AA | 1 |
| Searle, J | 1 |
| Green, JS | 1 |
| Lyburn, ID | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficiency and Safety of Nicotinamide-based Supportive Therapy in Lymphopenia for Patients With COVID-19: A Randomized Clinical Trial[NCT04910230] | 24 participants (Actual) | Interventional | 2020-03-01 | Completed | |||
| Nicotinamide Riboside in Ulcerative Colitis[NCT05561738] | 40 participants (Anticipated) | Interventional | 2024-01-01 | Not yet recruiting | |||
| A RANDOMIZED NON-COMPARATIVE PHASE 2 PILOT STUDY TESTING THE VALUE OF IMATINIB MESYLATE AS AN EARLY TREATMENT OF COVID-19 DISEASE IN AGED HOSPITALIZED PATIENTS.[NCT04357613] | Phase 2 | 99 participants (Anticipated) | Interventional | 2020-09-01 | Not yet recruiting | ||
| Randomized Double-Blind Placebo-Controlled Trial on the Safety and Efficacy of Imatinib for Hospitalized Adults With COVID-19[NCT04394416] | Phase 3 | 204 participants (Anticipated) | Interventional | 2020-06-02 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for niacinamide and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
COVID-19: Are We Facing Secondary Pellagra Which Cannot Simply Be Cured by Vitamin B3?
Topics: COVID-19; Humans; NAD; Niacin; Niacinamide; Pellagra; SARS-CoV-2 | 2022 |
Nicotinamide Riboside-The Current State of Research and Therapeutic Uses.
Topics: Aging; Animals; Betacoronavirus; Biological Availability; Cardiovascular Diseases; Coronavirus Infec | 2020 |
Minireview Exploring the Biological Cycle of Vitamin B3 and Its Influence on Oxidative Stress: Further Molecular and Clinical Aspects.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; Dysbiosis; Gastrointestinal Microbiome; Humans; N | 2020 |
Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide.
Topics: Basic Helix-Loop-Helix Transcription Factors; Betacoronavirus; Cell Line; Coronavirus Infections; CO | 2020 |
Nicotinamide pathways as the root cause of sepsis - an evolutionary perspective on macrophage energetic shifts.
Topics: Animals; Biological Evolution; COVID-19; Energy Metabolism; Humans; Macrophages; Niacinamide; Sepsis | 2022 |
4 trials available for niacinamide and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
[The result of prospective randomized study CITADEL - the efficacy and safety of drug cytoflavin in postcovid rehabilitation].
Topics: Adult; COVID-19; Drug Combinations; Female; Flavin Mononucleotide; Humans; Inosine Diphosphate; Male | 2021 |
Efficiency of nicotinamide-based supportive therapy in lymphopenia for patients with ordinary or severe COVID-19: A randomized controlled trial.
Topics: COVID-19; Hospital Mortality; Humans; Lymphopenia; Niacinamide; SARS-CoV-2 | 2022 |
Topical niacinamide (Nicotinamide) treatment for discoid lupus erythematosus (DLE): A prospective pilot study.
Topics: COVID-19; Humans; Lupus Erythematosus, Cutaneous; Lupus Erythematosus, Discoid; Niacinamide; Pilot P | 2023 |
Patients' willingness to accept adverse event and cost tradeoffs from oral nicotinamide for reduced risk of non-melanoma skin cancer.
Topics: Adult; Aged; COVID-19; Female; Humans; Logistic Models; Male; Niacinamide; Pandemics; Skin Neoplasms | 2023 |
8 other studies available for niacinamide and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
[The effectiveness of cytoflavin in complex therapy of patients with the coronavirus infection COVID-19].
Topics: COVID-19; Drug Combinations; Flavin Mononucleotide; Humans; Inosine Diphosphate; Niacinamide; SARS-C | 2021 |
[Evaluation of the effectiveness of the drug Cytoflavin in patients with dyscirculatory encephalopathy who have undergone a new coronavirus infection].
Topics: Aged; Brain Diseases; COVID-19; Female; Humans; Inosine Diphosphate; Male; Middle Aged; Niacinamide | 2023 |
Niacinamide enhances cathelicidin mediated SARS-CoV-2 membrane disruption.
Topics: Antimicrobial Cationic Peptides; Antiviral Agents; Cathelicidins; COVID-19; Humans; Niacinamide; SAR | 2023 |
A Second Look at Niacin.
Topics: COVID-19; Humans; Niacin; Niacinamide; Skin; Skin Diseases | 2023 |
Imatinib is not a potent anti-SARS-CoV-2 drug.
Topics: Antiviral Agents; Betacoronavirus; Caco-2 Cells; Coronavirus Infections; COVID-19; Drug Repositionin | 2020 |
Imatinib is not a potent anti-SARS-CoV-2 drug.
Topics: Antiviral Agents; Betacoronavirus; Caco-2 Cells; Coronavirus Infections; COVID-19; Drug Repositionin | 2020 |
Imatinib is not a potent anti-SARS-CoV-2 drug.
Topics: Antiviral Agents; Betacoronavirus; Caco-2 Cells; Coronavirus Infections; COVID-19; Drug Repositionin | 2020 |
Imatinib is not a potent anti-SARS-CoV-2 drug.
Topics: Antiviral Agents; Betacoronavirus; Caco-2 Cells; Coronavirus Infections; COVID-19; Drug Repositionin | 2020 |
The specific metabolome profiling of patients infected by SARS-COV-2 supports the key role of tryptophan-nicotinamide pathway and cytosine metabolism.
Topics: Aged; Aged, 80 and over; Betacoronavirus; Biomarkers; Coronavirus Infections; COVID-19; Cytosine; Ea | 2020 |
Coronavirus infection and PARP expression dysregulate the NAD metabolome: An actionable component of innate immunity.
Topics: A549 Cells; Adenosine Diphosphate Ribose; ADP-Ribosylation; Adult; Animals; Cell Line, Tumor; COVID- | 2020 |
COVID-19-Related Lung Parenchymal Uptake on 18F-PSMA-1007 PET/CT.
Topics: Aged; COVID-19; Edetic Acid; Humans; Lung; Male; Neoplasm Staging; Niacinamide; Oligopeptides; Posit | 2021 |